Itraconazole (Sporanox)

Itraconazole, marketed under the brand name Sporanox among others, is a triazole antifungal medication widely used in veterinary medicine to treat various fungal infections in cats. This versatile antifungal agent has become one of the most commonly prescribed oral antifungal medications for feline patients due to its broad spectrum of activity against both superficial and systemic fungal pathogens. Itraconazole offers effective treatment for conditions ranging from common dermatophytosis (ringworm) to serious systemic mycoses, making it an invaluable tool in the veterinary antifungal armamentarium.

Itraconazole works by inhibiting the fungal cytochrome P450 enzyme lanosterol 14-alpha-demethylase, which is essential for the synthesis of ergosterol, a critical structural component of fungal cell membranes. By blocking ergosterol production, itraconazole causes alterations in membrane permeability and cell wall integrity, ultimately inhibiting fungal growth. This mechanism of action provides activity against a wide range of pathogenic fungi including dermatophytes such as Microsporum and Trichophyton species, dimorphic fungi causing systemic mycoses, yeasts including Cryptococcus and some Candida species, and filamentous fungi such as Aspergillus species.

Itraconazole is available in several formulations including capsules containing coated beads, an oral solution, and various compounded preparations designed specifically for veterinary use. The oral solution has superior bioavailability compared to capsules and is often preferred when available, though capsules can be effective when administered appropriately with food. The drug is highly lipophilic and concentrates in fatty tissues, skin, and sebaceous secretions, achieving tissue concentrations that may exceed plasma levels. This characteristic makes itraconazole particularly effective for treating skin and nail infections.

The safety profile of itraconazole in cats is generally favorable compared to some other systemic antifungal options, though adverse effects including gastrointestinal upset and hepatotoxicity can occur. The medication requires veterinary prescription and supervision, with appropriate monitoring for adverse effects during extended treatment courses. Itraconazole has become a first-line choice for many feline fungal infections due to its combination of efficacy, acceptable safety profile, and practical once-daily oral dosing that allows for convenient home treatment by pet owners.

Dermatophytosis, commonly known as ringworm, represents one of the most common indications for itraconazole therapy in cats. Feline ringworm, most often caused by Microsporum canis, is a highly contagious fungal infection affecting the skin and hair coat that frequently requires systemic antifungal therapy for resolution. Itraconazole has become a preferred oral treatment for feline dermatophytosis due to its excellent activity against dermatophyte fungi combined with a favorable safety profile that allows it to be used in cats that may not be suitable candidates for older antifungals like griseofulvin. Treatment typically continues for several weeks until fungal cultures confirm eradication.

Cryptococcosis is another major indication for itraconazole use in cats. This systemic fungal infection, caused by Cryptococcus neoformans or Cryptococcus gattii, is one of the most common systemic mycoses in feline patients and can affect the nasal cavity, skin, eyes, and central nervous system. Itraconazole is frequently used for treating cryptococcosis, particularly when the infection is localized to the nasal cavity or skin without significant central nervous system involvement. For cases with CNS disease, fluconazole may be preferred due to its superior penetration into cerebrospinal fluid, but itraconazole remains an effective option for many presentations of feline cryptococcosis.

Sporotrichosis, caused by the dimorphic fungus Sporothrix schenckii, is an important indication for itraconazole in cats. Feline sporotrichosis can present with cutaneous lesions, lymphocutaneous spread, and occasionally disseminated disease. The infection is zoonotic and poses a significant transmission risk to humans, particularly in certain geographic regions. Itraconazole is considered a first-line treatment for feline sporotrichosis and is typically continued for extended periods to ensure complete eradication of the organism.

Other systemic fungal infections that may be treated with itraconazole include blastomycosis, histoplasmosis, and coccidioidomycosis, though these infections are less common in cats than in some other species. Aspergillosis, which in cats most commonly presents as sinonasal infection, may also be treated with itraconazole as part of a multimodal approach that often includes topical therapy and surgical debridement. The broad spectrum of activity against various fungal pathogens makes itraconazole a versatile choice when systemic antifungal therapy is needed.

Veterinarians select itraconazole based on multiple factors including the specific fungal organism involved, the location and extent of infection, the cat's overall health status, potential drug interactions, and practical considerations. Itraconazole offers advantages including oral administration for convenient home treatment, once-daily dosing in most cases, excellent tissue penetration particularly in skin and fatty tissues, and the ability to use the medication in FIV-positive cats and other patients who may not tolerate alternative antifungals.

Dosing of itraconazole for cats is determined by the veterinarian based on the type and severity of infection, the cat's body weight, and the specific formulation being used. Standard dosing typically involves once-daily administration, though some protocols may use twice-daily dosing initially or for certain infections. The veterinarian will calculate the appropriate dose based on the individual patient's weight and clinical circumstances, and these instructions should be followed precisely to ensure treatment effectiveness while minimizing the risk of adverse effects.

The oral solution formulation of itraconazole generally has superior bioavailability compared to capsules and may be preferred when available. The solution can be administered directly into the mouth using an oral dosing syringe, and it should be given without food for optimal absorption. In contrast, itraconazole capsules should be administered with food, particularly a meal containing some fat, as this significantly improves absorption of the medication from the capsule formulation. The difference in absorption requirements between formulations is important and should be followed as directed.

Treatment duration with itraconazole varies considerably depending on the type of infection being treated. Dermatophytosis typically requires treatment for a minimum of three to four weeks, continuing until fungal cultures are negative, which may take six weeks or longer in some cases. Systemic fungal infections such as cryptococcosis often require extended treatment courses of several months or longer, with therapy typically continued for two to three months beyond resolution of clinical signs. The veterinarian will determine appropriate treatment duration based on the specific infection and response to therapy.

Pulse therapy protocols, in which itraconazole is given for a period of days followed by a drug-free interval before the next treatment pulse, have been used for treating dermatophytosis in cats. This approach takes advantage of the drug's persistence in skin and hair follicles during the off-treatment period while potentially reducing the risk of adverse effects and treatment cost. The veterinarian will advise whether continuous daily therapy or a pulse protocol is most appropriate for the individual patient.

If a dose is missed, it should be given as soon as remembered unless it is close to the time for the next scheduled dose. In that case, the missed dose should be skipped and the regular schedule resumed. Doses should never be doubled to make up for missed doses. If multiple doses are missed or if there are concerns about treatment compliance, the veterinarian should be contacted for guidance.

Completing the full course of itraconazole therapy as prescribed is essential for successful treatment of fungal infections. Stopping treatment prematurely can allow the infection to relapse and may contribute to the development of antifungal resistance. Regular follow-up appointments allow the veterinarian to assess treatment response and determine when therapy can safely be discontinued.

Itraconazole is generally well tolerated in cats, with most patients completing treatment courses without experiencing significant adverse effects. However, as with any medication, side effects can occur, and pet owners should be aware of potential problems that may develop during therapy. The safety profile of itraconazole is considered favorable compared to some older antifungals, but monitoring for adverse effects remains important throughout treatment.

Gastrointestinal side effects are the most commonly reported adverse reactions to itraconazole in cats. Decreased appetite is a relatively frequent occurrence and may be dose-related. Some cats develop more significant anorexia that can lead to weight loss if not addressed. Nausea, vomiting, and diarrhea may also occur. These effects are often most pronounced during the initial period of treatment and may diminish as the cat adjusts to the medication. Dividing the daily dose into twice-daily administration or temporarily reducing the dose may help manage gastrointestinal effects in some cases.

Hepatotoxicity, or liver damage, is a recognized potential adverse effect of itraconazole and all azole antifungal medications. Elevated liver enzymes may be detected on blood work before clinical signs of liver disease become apparent. Signs of more significant liver problems may include decreased appetite, vomiting, jaundice (yellowing of the skin, gums, or whites of the eyes), lethargy, and changes in behavior. Regular monitoring of liver enzymes through blood work is advisable during extended itraconazole therapy, particularly during the first several weeks of treatment when hepatotoxicity is most likely to develop. If significant elevations occur, dose reduction or discontinuation of therapy may be necessary.

Skin and coat changes have been reported in some cats receiving itraconazole, including vasculitis (inflammation of blood vessels) affecting the skin and footpads. Limping, swelling of the paws, and skin ulceration may occur. These effects appear to be more common with higher doses or longer treatment courses. If signs of vasculitis develop, the veterinarian should be contacted promptly as discontinuation of the medication is typically required.

Rare adverse effects that have been reported include neurological signs such as depression or behavioral changes. Allergic reactions, while uncommon, can occur and may manifest as facial swelling, hives, or more severe systemic reactions. Any unusual symptoms or changes in the cat's condition during itraconazole therapy should be reported to the veterinarian for evaluation.

Itraconazole is contraindicated in cats with known hypersensitivity or previous allergic reactions to itraconazole or other azole antifungal medications. Cats that have experienced severe reactions such as anaphylaxis, significant skin eruptions, or other serious adverse effects with itraconazole or related drugs should not receive this medication again. Cross-reactivity between different azole antifungals is possible, and a history of adverse reactions to any medication in this drug class should be disclosed to the veterinarian.

Significant liver disease is a contraindication to itraconazole therapy due to the drug's potential hepatotoxicity and its dependence on liver metabolism for elimination. Cats with pre-existing liver dysfunction are at increased risk for developing serious liver problems during treatment and may also have altered drug metabolism that affects itraconazole blood levels. If itraconazole is deemed necessary in a cat with mild liver compromise, enhanced monitoring with more frequent blood work is essential. For cats with more significant liver disease, alternative antifungal medications may be more appropriate.

Congestive heart failure is listed as a contraindication for itraconazole in humans due to the drug's potential negative inotropic effects, and this concern may apply to cats with cardiac disease as well. Cats with known heart conditions, particularly those with reduced cardiac function, should be evaluated carefully before itraconazole is prescribed. The veterinarian will consider the severity of the fungal infection against the potential cardiac risks when making treatment decisions for cats with heart disease.

The safety of itraconazole in pregnant cats has not been definitively established, and the drug should be used during pregnancy only when the benefits clearly outweigh the potential risks. Itraconazole has been associated with fetal abnormalities in some species at high doses. Nursing cats should also be treated with caution, as itraconazole is excreted in milk and could potentially affect nursing kittens. The veterinarian will carefully consider these factors when treating pregnant or nursing cats with fungal infections.

Certain drug interactions may represent relative contraindications to itraconazole use. Cats receiving medications that are extensively metabolized by cytochrome P450 enzymes may experience significant interactions when itraconazole is added. A complete medication history is essential before starting itraconazole therapy to identify potential interactions that could affect treatment safety or efficacy.

Itraconazole has significant potential for drug interactions due to its inhibition of cytochrome P450 enzymes, particularly CYP3A4, which are involved in the metabolism of many medications. Before starting itraconazole therapy, it is essential that the veterinarian be informed of all medications, supplements, and over-the-counter products the cat is currently receiving. This comprehensive disclosure allows for identification of potential interactions and appropriate management.

One of the most clinically significant interactions involves ciclosporin (cyclosporine), a medication used in cats for various immune-mediated conditions. Itraconazole markedly inhibits cyclosporine metabolism, leading to substantially increased cyclosporine blood levels and potential toxicity. When these medications must be used together, significant reduction of the cyclosporine dose (often by 50% or more) is required, and close monitoring of cyclosporine levels is essential. Similarly, tacrolimus, another immunosuppressive drug, may have increased levels when combined with itraconazole.

Certain medications should not be used concurrently with itraconazole due to the risk of serious adverse effects. Cisapride, a gastrointestinal motility agent, can cause life-threatening cardiac arrhythmias when combined with itraconazole and should be avoided. Other medications that affect heart rhythm may also have enhanced effects when combined with itraconazole, and cats with cardiac conditions require careful evaluation.

Medications that reduce stomach acid, including antacids, H2 receptor antagonists, and proton pump inhibitors, can significantly reduce absorption of itraconazole capsules, which require an acidic environment for optimal dissolution and absorption. If acid-reducing medications are necessary, alternative itraconazole formulations such as the oral solution (which does not depend on stomach acid for absorption) may be preferred. Timing of administration can also help minimize this interaction.

Benzodiazepines and certain other sedative medications may have prolonged effects when combined with itraconazole due to inhibition of their metabolism. If sedation is required in a cat receiving itraconazole, dose adjustments may be necessary. Certain antibiotics, calcium channel blockers, and various other medications can interact with itraconazole through similar mechanisms.

Throughout itraconazole therapy, any new medications should be discussed with the veterinarian before they are administered. Regular monitoring through blood work helps identify problems early, and prompt reporting of any unusual symptoms allows for timely adjustment of the treatment regimen if drug interactions are suspected.

Several important precautions should be observed when using itraconazole to treat fungal infections in cats. Proper diagnosis of the fungal infection before initiating therapy is essential, as itraconazole is most effective against certain types of fungi and inappropriate use delays appropriate treatment while potentially causing unnecessary side effects. Diagnostic testing helps confirm the type of infection and ensures that antifungal therapy is warranted.

Regular monitoring through blood work is strongly recommended during itraconazole therapy, particularly during extended treatment courses. Baseline evaluation of liver function before starting treatment provides a comparison point for subsequent monitoring. Periodic rechecking of liver enzymes, typically within the first two to four weeks of therapy and then at regular intervals thereafter, allows early detection of hepatotoxicity. If significant liver enzyme elevations occur, dose reduction, temporary discontinuation, or switching to an alternative antifungal may be necessary.

Accurate weighing of the cat is important for calculating the correct dose of itraconazole. Using a reliable scale and weighing the cat periodically during treatment helps ensure appropriate dosing, particularly as cats may gain or lose weight during the course of their illness and treatment. Any significant weight changes should be reported to the veterinarian so that dose adjustments can be made if necessary.

The formulation of itraconazole being used affects administration requirements. Capsules should be given with food to enhance absorption, while the oral solution should be given on an empty stomach for optimal absorption. Following the appropriate administration instructions for the specific formulation prescribed helps ensure therapeutic drug levels are achieved.

Geriatric cats may have reduced liver and kidney function that affects drug metabolism and elimination, potentially requiring dose adjustments or enhanced monitoring. Kittens can develop dermatophytosis and may require itraconazole treatment, but careful attention to dosing based on body weight is essential. Immunocompromised cats, including those with FIV, can generally receive itraconazole (unlike griseofulvin), but may require more aggressive or prolonged therapy to clear fungal infections.

For zoonotic fungal infections such as sporotrichosis and ringworm, appropriate precautions should be taken to minimize transmission risk to human family members while the cat is being treated. This includes regular handwashing, minimizing handling of the infected cat, wearing gloves when applying topical treatments, and monitoring family members for signs of infection.

Itraconazole capsules should be stored at controlled room temperature, typically between 15 and 30 degrees Celsius (59 to 86 degrees Fahrenheit), in a dry location protected from light and moisture. The medication should be kept in its original container with the cap tightly closed. Avoiding storage in humid environments such as bathrooms helps maintain the medication's stability. Do not remove capsules from their original packaging until ready to administer, as this protects them from environmental degradation.

The oral solution formulation of itraconazole has specific storage requirements that should be followed carefully. Depending on the product, the solution may need to be stored at room temperature and protected from freezing. The container should be kept tightly closed when not in use, and the solution should not be exposed to excessive heat or light. The oral dosing syringe provided with the solution should be rinsed after each use and stored with the medication.

Compounded itraconazole preparations, which are sometimes used in veterinary medicine to provide appropriate dosing for cats, may have different storage requirements depending on the compounding pharmacy and the specific formulation. The instructions provided by the compounding pharmacy should be followed carefully. Compounded preparations may have shorter expiration periods than commercially manufactured products.

Expiration dates should be checked before each dose is administered, and any medication that has passed its expiration date should be properly disposed of and replaced. Using expired medication may result in reduced effectiveness due to degradation of the active ingredient, potentially compromising treatment of the fungal infection. If treatment needs to continue beyond the medication's expiration date, a fresh supply should be obtained.

Itraconazole should be stored securely out of reach of children and other pets to prevent accidental ingestion. The medication is intended only for the patient it was prescribed for and should not be shared with other animals even if they appear to have similar problems. Proper disposal of unused or expired itraconazole should be done through medication take-back programs or according to local guidelines for pharmaceutical waste disposal.

Itraconazole is generally safe for use in cats of all breeds, and there are no well-documented breed-specific contraindications or sensitivities to this antifungal medication. The drug's metabolism and effects do not appear to vary significantly based on breed in cats, allowing broad application across different feline populations. However, individual variation in drug response exists within all breeds, and appropriate monitoring is important for all patients.

Certain breeds may have predispositions to conditions that affect treatment considerations. Persian and Himalayan cats have higher rates of dermatophytosis (ringworm), making itraconazole therapy commonly needed in these breeds. The long coats of these breeds may also harbor fungal spores more readily and contribute to environmental contamination, often necessitating more aggressive treatment approaches including systemic antifungal therapy. Breeds with known predispositions to liver disease may warrant enhanced hepatic monitoring during itraconazole treatment.

Longhaired cat breeds generally benefit from coat clipping in conjunction with systemic itraconazole therapy when treating dermatophytosis. Clipping removes infected hairs that serve as a source of fungal spores, improves contact of topical treatments with the skin, and facilitates environmental decontamination by reducing shedding of contaminated hairs. The veterinarian or a groomer can perform appropriate clipping while minimizing skin irritation.

Size variations among cat breeds are relevant for accurate dosing. Larger cats require appropriately higher doses based on body weight, while smaller cats and individuals need proportionally smaller amounts. Body condition should be considered, as dosing based on actual body weight in an overweight or obese cat may result in higher than optimal drug levels. Accurate weighing and appropriate dose calculation are important regardless of breed.

Age-related considerations apply across all breeds. Kittens, which are particularly susceptible to dermatophytosis, can receive itraconazole with appropriate weight-based dosing. Very young kittens may be more sensitive to adverse effects and require careful monitoring. Geriatric cats commonly have some degree of reduced liver and kidney function that can affect drug metabolism and elimination. The veterinarian will consider individual patient factors including breed characteristics, age, and overall health status when prescribing itraconazole and determining monitoring protocols.

Several other antifungal medications may be considered as alternatives to itraconazole depending on the specific fungal organism involved, the type and location of infection, and individual patient factors. Fluconazole is another triazole antifungal commonly used for fungal infections in cats. Compared to itraconazole, fluconazole offers superior penetration into the central nervous system and urinary tract, making it the preferred choice for cryptococcal meningitis and fungal urinary tract infections. However, fluconazole has a narrower spectrum of activity and may be less effective against dermatophytes and certain other fungi.

Terbinafine is an allylamine antifungal that has become increasingly popular for treating dermatophytosis in cats. This medication concentrates in keratinized tissues and offers excellent activity against dermatophyte fungi, often allowing for shorter treatment courses compared to itraconazole or other antifungals. Terbinafine may be used alone or in combination with itraconazole for difficult-to-treat cases of ringworm. The medication is generally well-tolerated but can cause gastrointestinal upset and hepatotoxicity.

Griseofulvin is an older antifungal medication that was once the mainstay of dermatophytosis treatment. While effective against dermatophytes, griseofulvin has significant limitations including teratogenicity (making it absolutely contraindicated in pregnant cats) and bone marrow toxicity risk in FIV-positive cats. Itraconazole has largely replaced griseofulvin as a first-line treatment for many cats due to its broader safety profile.

Ketoconazole is an older azole antifungal that may be used for certain fungal infections when other agents are not available or suitable. However, ketoconazole has a higher incidence of hepatotoxicity and other adverse effects compared to newer triazoles like itraconazole, and it is generally not a first-choice medication. Voriconazole and posaconazole are newer triazole antifungals with expanded spectrums that may be used for resistant infections or specific fungal organisms, though veterinary experience with these drugs is more limited.

Topical antifungal treatments are often used in conjunction with systemic itraconazole therapy, particularly for dermatophytosis. Options include miconazole, clotrimazole, and antifungal shampoos. Lime sulfur dip remains an effective topical treatment for ringworm. Combination therapy with both topical and systemic antifungals helps reduce environmental contamination while the systemic medication addresses the infection within the skin and hair follicles. The veterinarian will determine the most appropriate combination of treatments based on the individual case.